Key Takeaways
- Merck and Moderna’s INTerpath-001 Phase 3 study successfully achieved its primary recurrence-free survival goal in melanoma patients
- The study included 1,137 participants with high-risk Stage IIB-IV melanoma and represents the first major Phase 3 success for mRNA cancer immunotherapy
- MRK shares reached a fresh 52-week peak of $143.52 during premarket hours, climbing approximately 10%
- Moderna’s stock skyrocketed more than 90% in premarket activity, reaching $118.61
- Barclays projects the treatment could achieve roughly $3 billion in melanoma-related revenue by 2035
Merck shares soared approximately 10% during Wednesday’s premarket session following the pharmaceutical giant’s announcement with Moderna regarding a significant breakthrough in their collaborative personalized mRNA cancer immunotherapy program.
The INTerpath-001 Phase 3 clinical study evaluating Intismeran autogene in combination with Keytruda successfully achieved both its primary recurrence-free survival objective and the secondary distant metastasis-free survival goal among patients with fully resected Stage IIB-IV melanoma.
MRK touched $143.52 during premarket trading, establishing a new 52-week record and surpassing the previous peak of $137.98.
The clinical trial recruited 1,137 high-risk participants following surgical melanoma removal. Study participants were administered up to nine doses of Keytruda combined with the personalized immunotherapy, or Keytruda as a standalone treatment, over roughly one year. The safety profile remained consistent with no unexpected adverse events.
This achievement represents the first successful late-stage clinical trial outcome for an mRNA-based cancer vaccine and the inaugural study demonstrating superior efficacy compared to Keytruda monotherapy in this patient population.
The findings build upon encouraging Phase 2b data released in January, which demonstrated the combination therapy decreased recurrence or death risk by 49% over five years versus Keytruda alone.
Moderna experienced a dramatic surge exceeding 90% in premarket activity following the announcement, reaching $118.61. Moderna became the most-discussed stock on Stocktwits after the news broke.
Regulatory Discussions on the Horizon
Merck’s research and development chief Dean Li told CNBC that both companies anticipate initiating regulatory conversations in the coming months. Moderna’s CEO Stephane Bancel confirmed pricing strategies remain undetermined, emphasizing the data “only became available a couple days ago.”
Bancel highlighted that Intismeran doesn’t require patients’ own cells, distinguishing it from certain cell therapies, which may enable more efficient manufacturing scalability and potentially reduce production costs.
J.P. Morgan analysts indicated the vaccine’s commercial launch for adjuvant melanoma treatment will be crucial for Moderna’s return to profitability. Barclays forecasts the therapy may generate approximately $3 billion in melanoma-specific sales by 2035.
Wall Street Upgrades Provided Additional Momentum
The trial success arrived following several favorable analyst actions. Daiwa elevated MRK to Outperform from Neutral on August 17, highlighting pipeline advancement. Wells Fargo initiated coverage with a Buy rating on the same date.
William Blair analyst Myles Minter stated the interim findings position both pharmaceutical companies favorably for regulatory approval pursuit, and the results appear promising for ongoing trials targeting additional cancer types. Further Phase 3 studies examining non-small cell lung cancer continue patient enrollment.
The overall market showed minimal movement on Wednesday, with the S&P 500 advancing just 0.1% and the Nasdaq marginally lower, indicating MRK’s surge was entirely driven by company-specific developments.
Merck is presently trading at its new 52-week high of $143.52 as of Wednesday’s premarket session.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
